{"classes":[{"categories":[{"measurements":[{"comment":"Data not evaluable due to a single loss of response with few subjects having spleen measurement follow-up data beyond 128 weeks from start of response.","groupId":"OG000","lowerLimit":"107.6","upperLimit":"NA","value":"135.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"}],"units":"Participants"}],"description":"The duration of ≥ 35% reduction from Baseline in spleen volume was defined as the longest duration of consecutive measurements of ≥ 35% reduction observed before the data cut-off date for patients who had at least one measured ≥ 35% reduction, and who either had at least one subsequent measurement or, who subsequently dropped out prior to another assessment. The duration of a ≥ 35% reduction from Baseline in spleen volume was analyzed using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants began treatment with ruxolitinib 15 or 20 mg taken orally twice a day based on Baseline platelet count. The dose was adjusted by the Investigator based on efficacy and safety to a maximum of 25 mg twice daily.","id":"OG000","title":"Ruxolitinib"}],"paramType":"MEDIAN","populationDescription":"Patients who had at least 1 measurement of ≥ 35% reduction from Baseline in spleen volume at any time during the study and had at least 1 subsequent measurement or withdrew prior to another assessment.","reportingStatus":"POSTED","timeFrame":"Baseline Visit and every 12 weeks until the data cut-off date (up to 14 months).","title":"Duration of Maintenance of a ≥ 35% Reduction From Baseline in Spleen Volume Among Patients Initially Randomized to Receive Ruxolitinib","type":"SECONDARY","unitOfMeasure":"weeks"}